Baseline characteristics of the entire study population and according to the presence or absence of MACE, which was the composite endpoint
| Variables | Total | MACE absent | MACE present | p Value |
|---|---|---|---|---|
| Number | 955 | 694 (72.7) | 261 (27.3) | |
| Aldosterone (pmol/l)* | 997.3 (499.3–1785.7) | 950.4 (474.3–1700.0) | 1150.1 (578.1–2064.2) | 0.0118 |
| Age | 66.5 (12.8) | 64.3 (12.4) | 72.3 (11.7) | <0.0001 |
| Male | 667 (69.8%) | 510 (73.5%) | 157 (60.2%) | <0.001 |
| Female | 288 (30.2%) | 184 (26.5%) | 104 (39.9%) | <0.001 |
| Hypertension | 512 (53.6%) | 344 (49.6%) | 168 (64.4%) | <0.001 |
| Diabetes | 244 (25.6%) | 159 (22.9%) | 85 (32.6%) | 0.002 |
| Previous CAD | 356 (37.3%) | 230 (33.1%) | 126 (48.3%) | <0.001 |
| Smoking history | 410 (43.0%) | 318 (45.9%) | 92 (35.4%) | 0.004 |
| STEMI | 398 (41.7%) | 285 (41.1%) | 113 (43.3%) | 0.534 |
| eGFR (ml/min/1.73 m2) | 66.2 (19.9) | 69.4 (18.8) | 57.6 (20.6) | <0.0001 |
| Killip Class >1 | 376 (39.6%) | 225 (32.7%) | 151 (58.1%) | <0.001 |
| Heart failure | 41 (4.3%) | 28 (4.0%) | 13 (5.0%) | 0.520 |
| NTproBNP(pmol/l)* | 768.4 (255.2–2259.9) | 591.2 (182.2–1591.1) | 2036.1 (568.8–3908.4) | <0.0001 |
| ACEI or ARB | 766 (80.2%) | 576 (83.0%) | 190 (72.8%) | <0.001 |
| Betablockers | 757 (79.3%) | 574 (82.7%) | 183 (70.1%) | <0.001 |
| Diuretics | 244 (25.6%) | 141 (20.3%) | 103 (39.7%) | <0.001 |
| Statins | 811 (84.9%) | 614 (88.5%) | 197 (75.5%) | <0.001 |
| Aspirin | 803 (84.0%) | 601 (86.6%) | 202 (77.4%) | 0.001 |
| GRACE score | 151.2 (39.8) | 143.6 (36.6) | 171.9 (41.1) | <0.0001 |
Values are mean (SD) or number (%), except for aldosterone and NTproBNP which are median and IQR.
*Median and IQR.
ARB, angiotensin receptor blocker; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MACE, major adverse cardiovascular events; NTproBNP, N-terminal pro-B type natriuretic peptide; STEMI, ST elevation myocardial infarction; GRACE, global registry of acute coronary events.